Cargando…
The metalloproteinase ADAM10 requires its activity to sustain surface expression
The metalloproteinase ADAM10 critically contributes to development, inflammation, and cancer and can be controlled by endogenous or synthetic inhibitors. Here, we demonstrate for the first time that loss of proteolytic activity of ADAM10 by either inhibition or loss of function mutations induces rem...
Autores principales: | Seifert, Anke, Düsterhöft, Stefan, Wozniak, Justyna, Koo, Chek Z., Tomlinson, Michael G., Nuti, Elisa, Rossello, Armando, Cuffaro, Doretta, Yildiz, Daniela, Ludwig, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873107/ https://www.ncbi.nlm.nih.gov/pubmed/32372373 http://dx.doi.org/10.1007/s00018-020-03507-w |
Ejemplares similares
-
An overview of carbohydrate-based carbonic anhydrase inhibitors
por: Cuffaro, Doretta, et al.
Publicado: (2020) -
Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution
por: Calligaris, Matteo, et al.
Publicado: (2021) -
Discovery of Dimeric Arylsulfonamides as Potent ADAM8
Inhibitors
por: Cuffaro, Doretta, et al.
Publicado: (2021) -
Developments in Carbohydrate-Based Metzincin Inhibitors
por: Cuffaro, Doretta, et al.
Publicado: (2020) -
Bacterial Zinc Metalloenzyme Inhibitors: Recent Advances and Future Perspectives
por: Di Leo, Riccardo, et al.
Publicado: (2023)